Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.63 USD | -3.97% | -8.79% | -36.65% |
04-05 | Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday | MT |
04-04 | Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.65% | 328M | C | ||
+0.17% | 42.19B | B | ||
+44.30% | 40.15B | A | ||
-6.20% | 28.31B | C | ||
+5.23% | 24.63B | B- | ||
-24.79% | 18.2B | B | ||
+26.69% | 12.01B | C+ | ||
-3.13% | 11.76B | C+ | ||
+6.57% | 10.4B | B+ | ||
-18.08% | 9.94B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRBU Stock
- Ratings Caribou Biosciences, Inc.